← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Atux Iskay Group Llc
Plainsboro, NJ
$4,325,552
Total funding
6
Grants
Funding over time
peak $2M · FY2020–25$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,125,966 · 5
DOD$199,586 · 1
By mechanism
R44$2,516,671 · 1
R43$854,295 · 2
N43$755,000 · 2
—$199,586 · 1
Investigators at Atux Iskay Group Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Direct protein phosphatase 2A (PP2A) activators as novel Alzheimerâs Disease (AD) therapeutics$1,688,077
R44 · FY2024 · AG
Direct protein phosphatase 2A (PP2A) activators as novel Alzheimerâs Disease (AD) therapeutics$828,594
R44 · FY2025 · AG
Direct activators of protein phosphatase 2A (PP2A) as novel Alzheimer's Disease (AD) therapeutics$447,795
R43 · FY2020 · AG
Direct Activation of PP2A as a Novel Approach to Group-3 Medulloblastoma Therapy$406,500
R43 · FY2022 · CA
SBIR PHASE I TOPIC #446 - DEVELOPMENT OF SENOTHERAPEUTIC AGENTS FOR CANCER TREATMENT$400,000
N43 · FY2023 · CA
SBIR CONCEPT AWARD - THERAPEUTICS - SULFONYL-UREA AND SULFONAMIDE PP2A ACTIVATORS AS MYCN AMPLIFIED NEUROBLASTOMA (NBL) THERAPEUTICS$355,000
N43 · FY2024 · CA
PHARMACOLOGICAL ACTIVATION OF PP2A AS A NOVEL TREATMENT APPROACH FOR PULMONARY FIBROSIS$199,586
· FY2020 · Defense Health Agency